+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

China Oncology Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

  • PDF Icon

    Report

  • 145 Pages
  • February 2022
  • Region: China
  • Renub Research
  • ID: 5546211
China Oncology Drugs Market is anticipated to reach US$ 35.24 Billion by 2027. Cancer is among China’s high-priority disease areas, with patients experiencing a significant health burden. Hence, the cancer drugs industry is the fastest-growing central therapeutic area in China’s pharmaceutical market. In particular, the increasingly challenging treatment of complex, severe cancerous diseases through drugs has generated unmet medical needs, leading to the promising market potential of the China Cancer Drugs Market.





Further, the acceleration of innovation within the oncology drugs industry in China is critical to progress in managing China’s oncology burden. Exceptionally outpacing the growth rate of new cancer cases in China, the oncology drug market in China demonstrates robust growth.

China Oncology Drugs Market Size was US$ 23.70 Billion in 2021


Chinese Drugs Industry has been shaping initiatives grounded in the local environment, assuring that patients receive enhanced treatment options that are accessible and equitable to all. Moreover, recent trends fuelling China’s progress in cancer drugs are innovation. A wave of new biotech’s focused on oncology and improved quality in oncology research is boosting China’s Cancer Drugs Market.

In addition, other key growth drivers for the industry in China include the aging trend of the Chinese population, rising healthcare expenditure, and improving the public medical insurance system. Therefore, driven by multiple factors, the number of new cases of cancer in China treated by drugs has constantly been increasing. According to this report China Cancer Drug Industry is expanding at a CAGR of 6.8% during 2021-2027.

Targeted Therapy Is the Most Dominating Segment in China Oncology Drugs Market:


In our report, China Cancer Drug Market covers the cancer therapy market and the cancer drugs market. In terms of therapy, cancer treatment has gone through a long development process in history. Effective therapies include chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy.

In addition, cancer supportive care, which refers to the medical care that focuses on relieving the symptoms caused by cancer treatments to improve the quality of life, has also evolved with the development of various cancer treatment therapies. As per our analysis, By Therapy, Targeted Therapy is the most dominating segment in China Oncology Drug Market.

Lung Cancer Segment Occupies the Largest Oncology Drugs Market Share:


By Indication, our report covers Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, and Kidney Cancer existing in the market. In addition, China looks set to become a primary developer of cancer drugs for the diverse indications infusing regulatory changes to simplify and encourage drug development, which also opens the door for more significant investment by international pharmaceutical brands.

According to Indication, the lung oncology segment occupies the largest oncology drugs market share due to the vast geriatric population in China. Besides, the breast cancer segment is expected to experience the fastest growth due to technological developments in cancer diagnostics and a rise in awareness related to the early diagnosis of cancer.

Key Players:


The major players operating in the China Oncology Drugs Market include Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc. Companies have explored different development pathways to accelerate regulatory approval for faster patient access. Additionally, key players are increasingly entering into R&D partnerships with local Chinese companies to accelerate approval and bring treatment to patients. In addition, companies are also offering schemes to improve affordability to help patients get appropriate treatment.

The COVID-19 Pandemic Disrupted the China Oncology Drugs Market:


The COVID-19 pandemic has had widespread adverse collateral effects on China Cancer Drugs Market. Remarkably, China’s Oncology Drugs Industry was reliant on rapid testing and diagnosis and on timely and coordinated multimodal treatment, all of which had been impacted by the pandemic adversely. However, over time, the initial and enduring effects of the COVID-19 pandemic on the utilization of cancer drugs deteriorated.

This research report titled “China Oncology Drugs Market, by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) and Hormonal Therapy), Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, Other Cancers), Drugs ( ESAs (Erythropoiesis Stimulating Agents), G-CSFs (Granulocyte-colony Stimulating Factors), Anti-emetics, Bisphosphonates, Opioids, NSAIDs & Others), Companies (Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche AG, Johnson & Johnson, AbbVie Inc., AstraZeneca plc)” provides a complete analysis of China Oncology Drugs Market.

Therapy - Market have been covered from 4 viewpoints:


  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

Indication - Market have been covered from 10 viewpoints:


  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Lung Cancer
  • Skin Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Other Cancers

Drugs - Market have been covered from 6 viewpoints:


  • ESAs (Erythropoiesis Stimulating Agents)
  • G-CSFs (Granulocyte-colony Stimulating Factors)
  • Anti-emetics
  • Bisphosphonates
  • Opioids
  • NSAIDs & Others

Company Insights:


  • Overview
  • Recent Development & Strategies
  • Revenue Analysis

Company Analysis:


  • Bristol Myers Squibb
  • Merck
  • Eli Lilly
  • Sino BioPharma
  • F Hoffmann-La Roche AG
  • Johnson & Johnson
  • AbbVie Inc.
  • AstraZeneca plc
Frequently Asked Questions about the Chinese Oncology Drugs Market

What is the estimated value of the Chinese Oncology Drugs Market?

The Chinese Oncology Drugs Market was estimated to be valued at $23.7 Billion in 2021.

What is the growth rate of the Chinese Oncology Drugs Market?

The growth rate of the Chinese Oncology Drugs Market is 6.8%, with an estimated value of $35.24 Billion by 2027.

What is the forecasted size of the Chinese Oncology Drugs Market?

The Chinese Oncology Drugs Market is estimated to be worth $35.24 Billion by 2027.

Who are the key companies in the Chinese Oncology Drugs Market?

Key companies in the Chinese Oncology Drugs Market include Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann, La Roche AG, Johnson & Johnson and AstraZeneca plc.

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. China Cancer Drugs Market
6. Market Share - China Oncology Drugs Market
6.1 By Therapy
6.2 By Indication
6.3 By Drugs
7. Therapy- China Oncology Drugs Market
7.1 Chemotherapy
7.2 Targeted Therapy
7.3 Immunotherapy (Biologic Therapy)
7.4 Hormonal Therapy
8. Indication- China Oncology Drugs Market
8.1 Blood Cancer
8.2 Breast Cancer
8.3 Gastrointestinal Cancer
8.4 Prostate Cancer
8.5 Lung Cancer
8.6 Skin Cancer
8.7 Ovarian Cancer
8.8 Cervical Cancer
8.9 Kidney Cancer
8.11 Other Cancers
9. Drugs- China Oncology Drugs Market
9.1 ESAs (Erythropoiesis Stimulating Agents)
9.2 G-CSFs (Granulocyte-colony Stimulating Factors)
9.3 Anti-emetics
9.4 Bisphosphonates
9.5 Opioids
9.6 NSAIDs & Others
10. Porters Five Forces
10.1 Overview
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Degree of Competition
10.5 Threat of New Entrants
10.6 Threat of Substitutes
11. Company Analysis
11.1 Bristol Myers Squibb
11.1.1 Overview
11.1.2 Recent Development
11.1.3 Revenue Analysis
11.2 Merc
11.2.1 Overview
11.2.2 Recent Development
11.2.3 Revenue Analysis
11.3 Eli Lilly
11.3.1 Overview
11.3.2 Recent Development
11.3.3 Revenue Analysis
11.4 Sino BioPharma
11.4.1 Overvie
11.4.2 Recent Development
11.4.3 Revenue Analysis
11.5 F Hoffmann-La Roche A
11.5.1 Overview
11.5.2 Recent Development
11.5.3 Revenue Analysis
11.6 Johnson & Johnson
11.6.1 Overview
11.6.2 Recent Development
11.6.3 Revenue Analysis
11.7 AbbVie Inc.
11.7.1 Overview
11.7.2 Recent Development
11.7.3 Revenue Analysis
11.8 AstraZeneca plc
11.8.1 Overview
11.8.2 Recent Development
11.8.3 Revenue Analysis
List of Figures
Figure 01: China Cancer Drugs Market (Billion US$), 2018 - 2021
Figure 02: Forecast for - China Cancer Drugs Market (Billion US$), 2022 - 2027
Figure 03: Therapy - Chemotherapy Market (Billion US$), 2018 - 2021
Figure 04: Therapy - Forecast for Chemotherapy Market (Billion US$), 2022 - 2027
Figure 05: Therapy - Targeted Therapy Market (Billion US$), 2018 - 2021
Figure 06: Therapy - Forecast for Targeted Therapy Market (Billion US$), 2022 - 2027
Figure 07: Therapy - Immunotherapy (Biologic Therapy) Market (Billion US$), 2018 - 2021
Figure 08: Therapy - Forecast for Immunotherapy (Biologic Therapy) Market (Billion US$), 2022 - 2027
Figure 09: Therapy - Hormonal Therapy Market (Billion US$), 2018 - 2021
Figure 10: Therapy - Forecast for Hormonal Therapy Market (Billion US$), 2022 - 2027
Figure 11: Indication - Blood Cancer Market (Billion US$), 2018 - 2021
Figure 12: Indication - Forecast for Blood Cancer Market (Billion US$), 2022 - 2027
Figure 13: Indication - Breast Cancer Market (Billion US$), 2018 - 2021
Figure 14: Indication - Forecast for Breast Cancer Market (Billion US$), 2022 - 2027
Figure 15: Indication - Gastrointestinal Cancer Market (Billion US$), 2018 - 2021
Figure 16: Indication - Forecast for Gastrointestinal Cancer Market (Billion US$), 2022 - 2027
Figure 17: Indication - Prostate Cancer Market (Billion US$), 2018 - 2021
Figure 18: Indication - Forecast for Prostate Cancer Market (Billion US$), 2022 - 2027
Figure 19: Indication - Lung Cancer Market (Billion US$), 2018 - 2021
Figure 20: Indication - Forecast for Lung Cancer Market (Billion US$), 2022 - 2027
Figure 21: Indication - Skin Cancer Market (Billion US$), 2018 - 2021
Figure 22: Indication - Forecast for Skin Cancer Market (Billion US$), 2022 - 2027
Figure 23: Indication - Ovarian Cancer Market (Billion US$), 2018 - 2021
Figure 24: Indication - Forecast for Ovarian Cancer Market (Billion US$), 2022 - 2027
Figure 25: Indication - Cervical Cancer Market (Million US$), 2018 - 2021
Figure 26: Indication - Forecast for Cervical Cancer Market (Million US$), 2022 - 2027
Figure 27: Indication - Kidney Cancer Market (Billion US$), 2018 - 2021
Figure 28: Indication - Forecast for Kidney Cancer Market (Billion US$), 2022 - 2027
Figure 29: Indication - Other Cancers Market (Billion US$), 2018 - 2021
Figure 30: Indication - Forecast for Other Cancers Market (Billion US$), 2022 - 2027
Figure 31: Drugs - ESAs (Erythropoiesis Stimulating Agents) Market (Billion US$), 2018 - 2021
Figure 32: Drugs - Forecast for ESAs (Erythropoiesis Stimulating Agents) Market (Billion US$), 2022 - 2027
Figure 33: Drugs - G-CSFs (Granulocyte-colony Stimulating Factors) Market (Billion US$), 2018 - 2021
Figure 34: Drugs - Forecast for G-CSFs (Granulocyte-colony Stimulating Factors) Market (Billion US$), 2022 - 2027
Figure 35: Drugs - Anti-emetics (Billion US$), 2018 - 2021
Figure 36: Drugs - Forecast for Anti-emetics (Billion US$), 2022 - 2027
Figure 37: Drugs - Bisphosphonates (Billion US$), 2018 - 2021
Figure 38: Drugs - Forecast for Bisphosphonates (Billion US$), 2022 - 2027
Figure 39: Drugs - Opioids (Billion US$), 2018 - 2021
Figure 40: Drugs - Forecast for Opioids (Billion US$), 2022 - 2027
Figure 41: Drugs - NSAIDs & Others (Billion US$), 2018 - 2021
Figure 42: Drugs - Forecast for NSAIDs & Others (Billion US$), 2022 - 2027
Figure 43: Bristol Myers Squibb - Global Revenue (Billion US$), 2018 - 2021
Figure 44: Bristol Myers Squibb - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 45: Merck - Global Revenue (Billion US$), 2018 - 2021
Figure 46: Merck - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 47: Eli Lilly - Global Revenue (Billion US$), 2018 - 2021
Figure 48: Eli Lilly - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 49: Sino BioPharma - Global Revenue (Billion US$), 2018 - 2021
Figure 50: Sino BioPharma - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 51: F Hoffmann-La Roche AG - Global Revenue (Billion US$), 2018 - 2021
Figure 52: F Hoffmann-La Roche AG - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 53: Johnson & Johnson - Global Revenue (Billion US$), 2018 - 2021
Figure 54: Johnson & Johnson - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 55: AbbVie Inc. - Global Revenue (Billion US$), 2018 - 2021
Figure 56: AbbVie Inc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 57: AstraZeneca plc - Global Revenue (Billion US$), 2018 - 2021
Figure 58: AstraZeneca plc - Forecast for Global Revenue (Billion US$), 2022 - 2027
List of Tables
Table 01: China Cancer Drugs Market Share by Therapy (Percent), 2018 - 2021
Table 02: Forecast for - China Cancer Drugs Market Share by Therapy (Percent), 2022 - 2027
Table 03: China Cancer Drugs Market Share by Indication (Percent), 2018 - 2021
Table 04: Forecast for - China Cancer Drugs Market Share by Indication (Percent), 2022 - 2027
Table 05: China Cancer Drugs Market Share by Drugs (Percent), 2018 - 2021
Table 06: Forecast for - China Cancer Drugs Market Share by Drugs (Percent), 2022 - 2027

Companies Mentioned

  • Bristol Myers Squibb
  • Merck
  • Eli Lilly
  • Sino BioPharma
  • F Hoffmann-La Roche AG
  • Johnson & Johnson
  • AbbVie Inc.
  • AstraZeneca plc

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...